相关实验视频
Updated: Jan 29, 2026

09:02
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
7.9K
精神病患者的潜在药物相互作用 接受肝炎C病毒感染的泛型疗法
Dorota Dybowska1, Małgorzata Pawłowska1, Dorota Kozielewicz1
1Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland.
Pharmaceuticals (Basel, Switzerland)
|January 28, 2026
概括
直接作用抗病毒药物 (DAA) 对C型肝炎病毒 (HCV) 感染具有很高的疗效. 然而,对患有精神障碍的患者来说,管理DAA和精神药物之间的药物相互作用 (DDI) 是至关重要的.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 精神病学是一个精神病学.
- 临床药理学 临床药理学
背景情况:
- 慢性型肝炎病毒 (HCV) 感染治疗已通过直接作用抗病毒药物 (DAA) 取得显著进展.
- DAA具有很高的疗效和良好的耐受性,使其可供大多数患者使用,包括那些患有并发症的患者.
- 在患有精神疾病的患者中,HCV联合感染很常见,这带来了独特的治疗挑战.
研究的目的:
- 突出泛型DAA和精神药物之间的药物相互作用 (DDI) 的临床挑战.
- 强调了解这些DDI对于同时感染个体的有效患者管理的重要性.
主要方法:
- 对泛型型直接作用抗病毒疗法和常用的精神药物之间的显著药物相互作用的审查.
- 讨论重叠的代谢途径,有助于潜在的DDI.
主要成果:
- 虽然DAA疗法对HCV非常有效,但可以导致与精神药物有关的显著DDI.
- 这些相互作用可能会影响抗病毒和精神病治疗的疗效和安全性.
- 对特定相互作用的了解对于优化治疗结果至关重要.
结论:
- 使用DAA治疗精神疾病患者的HCV治疗时,管理药物相互作用是一个关键的临床挑战.
- 对DDI的认识和仔细考虑对于成功的患者管理和治疗疗效至关重要.
相关概念视频
Drug Therapy
269
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
269
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
227
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
227
Hepatic Drug Excretion: Influencing Factors
564
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
564
Hepatic Drug Clearance: Role of Transporters
307
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
307
Pharmacokinetics: Drug–Drug Interactions
430
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
430
Hepatic Drug Excretion: Enterohepatic Cycling
2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

